Utilization of Oncotype DX in an Inner City Population: Race or Place?
Oncotype DX, a 21-gene-array analysis, can guide chemotherapy treatment decisions for women with ER+ tumors. Of 225 ER+ women participating in a patient assistance trial, 23% underwent Oncotype DX testing: 31% of whites, 21% of blacks, and 14% of Hispanics (P=0.04) were tested. Only 3 white wome...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/653805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559081179578368 |
|---|---|
| author | Amber A. Guth Susan Fineberg Kezhen Fei Rebeca Franco Nina A. Bickell |
| author_facet | Amber A. Guth Susan Fineberg Kezhen Fei Rebeca Franco Nina A. Bickell |
| author_sort | Amber A. Guth |
| collection | DOAJ |
| description | Oncotype DX, a 21-gene-array analysis, can guide chemotherapy treatment decisions for women with ER+ tumors. Of 225 ER+ women participating in a patient assistance trial, 23% underwent Oncotype DX testing: 31% of whites, 21% of blacks, and 14% of Hispanics (P=0.04) were tested. Only 3 white women were treated at municipal hospitals and none was tested. 3% of women treated in municipal hospital as compared to 30% treated at tertiary referral centers were tested (P=0.001). Within tertiary referral centers, there was no racial difference in testing: 32% of whites, 29% of blacks, and 19% of Hispanics (P=0.25). Multivariate analysis (model c-statistic = 0.76; P<0.0001) revealed that women who underwent testing were more likely to have stage 1B (RR=1.70; 95% CI: 1.45–1.85) and to be treated after 2007 (RR=1.34; 95% CI: 1.01–1.65) and less likely to be treated at a municipal hospital (RR=0.20; 95% CI: 0.04–0.94). Women treated at municipal hospitals were less likely to undergo testing resulting in a misleading racial disparity that is driven by site of care. As Oncotype DX can reduce overuse of chemotherapy, it is imperative to expand testing to those who could benefit from yet experience underuse of this test, namely, women treated at safety net hospitals. This trial is registered with NCT00233077. |
| format | Article |
| id | doaj-art-7908eb6b3c724acdaac9bd09cd8291a4 |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-7908eb6b3c724acdaac9bd09cd8291a42025-02-03T01:30:51ZengWileyInternational Journal of Breast Cancer2090-31702090-31892013-01-01201310.1155/2013/653805653805Utilization of Oncotype DX in an Inner City Population: Race or Place?Amber A. Guth0Susan Fineberg1Kezhen Fei2Rebeca Franco3Nina A. Bickell4Division of Surgical Oncology, NYU-Langone Medical Center, 160 East 34th Street, 4th Floor, New York, NY 10016, USADepartment of Pathology, Montefiore Medical Center, Bronx, NY 10467, USADepartment of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY 10029, USADepartment of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY 10029, USADepartment of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY 10029, USAOncotype DX, a 21-gene-array analysis, can guide chemotherapy treatment decisions for women with ER+ tumors. Of 225 ER+ women participating in a patient assistance trial, 23% underwent Oncotype DX testing: 31% of whites, 21% of blacks, and 14% of Hispanics (P=0.04) were tested. Only 3 white women were treated at municipal hospitals and none was tested. 3% of women treated in municipal hospital as compared to 30% treated at tertiary referral centers were tested (P=0.001). Within tertiary referral centers, there was no racial difference in testing: 32% of whites, 29% of blacks, and 19% of Hispanics (P=0.25). Multivariate analysis (model c-statistic = 0.76; P<0.0001) revealed that women who underwent testing were more likely to have stage 1B (RR=1.70; 95% CI: 1.45–1.85) and to be treated after 2007 (RR=1.34; 95% CI: 1.01–1.65) and less likely to be treated at a municipal hospital (RR=0.20; 95% CI: 0.04–0.94). Women treated at municipal hospitals were less likely to undergo testing resulting in a misleading racial disparity that is driven by site of care. As Oncotype DX can reduce overuse of chemotherapy, it is imperative to expand testing to those who could benefit from yet experience underuse of this test, namely, women treated at safety net hospitals. This trial is registered with NCT00233077.http://dx.doi.org/10.1155/2013/653805 |
| spellingShingle | Amber A. Guth Susan Fineberg Kezhen Fei Rebeca Franco Nina A. Bickell Utilization of Oncotype DX in an Inner City Population: Race or Place? International Journal of Breast Cancer |
| title | Utilization of Oncotype DX in an Inner City Population: Race or Place? |
| title_full | Utilization of Oncotype DX in an Inner City Population: Race or Place? |
| title_fullStr | Utilization of Oncotype DX in an Inner City Population: Race or Place? |
| title_full_unstemmed | Utilization of Oncotype DX in an Inner City Population: Race or Place? |
| title_short | Utilization of Oncotype DX in an Inner City Population: Race or Place? |
| title_sort | utilization of oncotype dx in an inner city population race or place |
| url | http://dx.doi.org/10.1155/2013/653805 |
| work_keys_str_mv | AT amberaguth utilizationofoncotypedxinaninnercitypopulationraceorplace AT susanfineberg utilizationofoncotypedxinaninnercitypopulationraceorplace AT kezhenfei utilizationofoncotypedxinaninnercitypopulationraceorplace AT rebecafranco utilizationofoncotypedxinaninnercitypopulationraceorplace AT ninaabickell utilizationofoncotypedxinaninnercitypopulationraceorplace |